Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

Intern Med J. 2014 Dec;44(12b):1350-63. doi: 10.1111/imj.12599.


Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.

Keywords: Pneumocystis carinii; Pneumocystis jirovecii; haematological malignancy; prophylaxis; solid-organ tumour; treatment.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / adverse effects
  • Antibiotic Prophylaxis*
  • Consensus
  • Drug Administration Schedule
  • Humans
  • Immunocompromised Host / immunology*
  • Neoplasms / complications
  • Neoplasms / immunology*
  • Opportunistic Infections / immunology
  • Opportunistic Infections / microbiology*
  • Opportunistic Infections / prevention & control*
  • Pneumocystis carinii / pathogenicity*
  • Pneumonia, Pneumocystis / immunology
  • Pneumonia, Pneumocystis / microbiology
  • Pneumonia, Pneumocystis / prevention & control*
  • Practice Guidelines as Topic
  • Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage*


  • Adrenal Cortex Hormones
  • Trimethoprim, Sulfamethoxazole Drug Combination